0001789769-24-000027.txt : 20240214 0001789769-24-000027.hdr.sgml : 20240214 20240214160817 ACCESSION NUMBER: 0001789769-24-000027 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240212 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Instil Bio, Inc. CENTRAL INDEX KEY: 0001789769 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 832072195 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40215 FILM NUMBER: 24638010 BUSINESS ADDRESS: STREET 1: 3963 MAPLE AVENUE STREET 2: SUITE 350 CITY: DALLAS STATE: TX ZIP: 75219 BUSINESS PHONE: (972) 499-3350 MAIL ADDRESS: STREET 1: 3963 MAPLE AVENUE STREET 2: SUITE 350 CITY: DALLAS STATE: TX ZIP: 75219 8-K 1 til-20240212.htm 8-K til-20240212
FALSE000178976900017897692024-02-122024-02-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 12, 2024
Instil Bio, Inc.
(Exact name of registrant as specified in its Charter)
 
Delaware001-4021583-2072195
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
3963 Maple Avenue, Suite 350
Dallas, Texas
75219
(Address of Principal Executive Offices)(Zip Code)
(972) 499-3350
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
 Name of each exchange on which registered
Common Stock, $0.000001 par valueTILThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐  

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 12, 2024, Instil Bio, Inc. (the “Company”) entered into a 2024 Retention Bonus Agreement with each of Bronson Crouch, the Company’s Chief Executive Officer, and Sandeep Laumas, M.D., the Company’s Chief Financial Officer and Chief Business Officer (together, the “Retention Bonus Agreements”). Pursuant to the Retention Bonus Agreements, the Company agreed to pay a one-year retention bonus to each of Mr. Crouch and Dr. Laumas in the amount of $462,825 and $254,300, respectively (each, a “Retention Bonus”).

Pursuant to the terms of the Retention Bonus Agreements, Mr. Crouch and Dr. Laumas will earn the full amount of his respective Retention Bonus if he remains employed with the Company in good standing through February 12, 2025 (the “Retention Date”). In the event that the Company terminates the employment of Mr. Crouch or Dr. Laumas without Cause (as defined in the Retention Bonus Agreements) or Mr. Crouch or Dr. Laumas resigns his employment for Good Reason (as defined in the Retention Bonus Agreements), and other than as a result of death or disability, at any time prior to the Retention Date, then no portion of the Retention Bonus will be subject to repayment. In the event that Mr. Crouch or Dr. Laumas resigns his employment without Good Reason or his employment is terminated for Cause at any time on or prior to the Retention Date, then a pro-rated amount of such executive’s then unearned Retention Bonus will be subject to repayment to the Company within 30 days of termination.

The above description of the Retention Bonus Agreements is qualified in its entirety by reference to the complete terms and conditions as set forth in the Retention Bonus Agreements, the form of which is filed as Exhibit 10.1 to this Current Report and incorporated herein by reference.


Item 9.01 Financial Statements and Exhibits.

(d)Exhibits
 
Exhibit No. Description
10.1+ 
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
+ Indicates a management contractor compensatory plan.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  Instil Bio, Inc.
Dated:February 14, 2024  By: /s/ Sandeep Laumas, M.D.
   Sandeep Laumas, M.D.
   Chief Financial Officer and Chief Business Officer
(Principal Financial Officer and Principal Accounting Officer)

 EX-10.1 2 formofretentionbonusagreem.htm EX-10.1 Document
Exhibit 10.1
February 12, 2024

[Name and Title]

Re: 2024 Retention Bonus Agreement

Dear _____________:

As we have shared with you, Instil Bio, Inc. (the “Company”) is offering you the retention bonus described in this letter (this “2024 Retention Bonus Agreement” or this “Agreement”) as an incentive for your continued service to the Company over the next year.

If you sign this 2024 Retention Bonus Agreement, you will be eligible to earn a retention bonus in connection with your continued employment with the Company on the terms described below. Specifically, if you remain employed with the Company in good standing through February 12, 2025 (the “Retention Date”), you will earn a retention bonus in the amount of $[ ] (the “Retention Bonus”), less all applicable deductions and tax withholdings.

The Company will advance you a payment equal to the Retention Bonus, less all applicable deductions and tax withholdings, prior to its being earned, on the Company’s next regularly scheduled payroll date at least five (5) days after the date you and the Company sign this 2024 Retention Bonus Agreement.

In the event that the Company terminates your employment without Cause (as defined below), and other than as a result of your disability, provided such termination of employment is a “separation from service” as defined under Treasury Regulation Section 1.409A-1(h), at any time prior to the Retention Date, then you will not be obligated to repay any portion of the Retention Bonus previously received, provided that: (a) you continue to comply with your continuing obligations under all agreements entered into between you and the Company; and (b) you deliver to the Company (and do not later revoke) a general release of claims in favor of the Company (and its officers, directors, employees, and affiliates) in a form satisfactory to the Company and signed within the time period set forth therein .

In the event that you resign your employment for any reason or your employment is terminated by the Company for Cause at any time on or prior to the Retention Date, then you will be required to repay, and hereby agree to repay, a prorated amount of the unearned Retention Bonus that has been advanced to you under this Agreement calculated as if 1/12th of the Retention Bonus was earned for each full month of service between February 12, 2024 and February 12, 2025, within thirty (30) days of the termination of your employment with Instil Bio.

It is intended that all benefits and other payments under this 2024 Retention Bonus Agreement satisfy, to the greatest extent possible, the exemptions from the application of Internal Revenue Code Section 409A provided under Treasury Regulations 1.409A 1(b)(4) and 1.409A 1(b)(9); this 2024 Retention Bonus Agreement will be construed to the greatest extent possible as consistent with those provisions; and the timing of any such payments or benefits may be modified to satisfy those provisions.

For purposes of this Agreement only, “Cause” means your: (i) failure to substantially perform your duties and responsibilities to the Company or violation of a Company policy; (ii) commission or conviction (including a guilty plea or plea of nolo contendere) of any felony or any other crime involving fraud, dishonesty or moral turpitude; (iii) commission or attempted commission of or participation in a fraud or act of dishonesty or misrepresentation against the Company; (iv) material breach of your duties to the Company; (v) intentional damage to any property of the Company; (vi) misconduct, or other violation of Company policy that causes or is reasonably likely to cause harm; (vii) material violation of any written and
297175162 v1
[Executive Name]
February 12, 2024
Page 2 of 2
fully executed contract or agreement between you and the Company, including without limitation, material breach of any agreement between you and the Company regarding protection of confidential information or trade secrets, or of any Company policy, or of any statutory duty you owe to the Company; or (viii) conduct which in the good faith and reasonable determination of the Company demonstrates gross unfitness to serve.

Except as expressly stated herein, nothing in this 2024 Retention Bonus Agreement changes the terms and conditions of your employment with the Company. For example, nothing in this 2024 Retention Bonus Agreement alters the at-will nature of your employment or your right or the Company’s right to terminate your employment at any time, with or without Cause or advance notice.

This 2024 Retention Bonus Agreement constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This 2024 Retention Bonus Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This 2024 Retention Bonus Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of Delaware without respect to conflicts of law principles. This 2024 Retention Bonus Agreement may be executed in counterparts and electronic signatures and scanned image copies of signatures will suffice as original signatures.

If this 2024 Retention Bonus Agreement is acceptable to you, please sign below and return the original to me within five (5) days.

Sincerely,

Instil Bio, Inc.



By:



Accepted and Agreed:


______________________________________


______________________________________
Date
297175162 v1
 EX-101.SCH 3 til-20240212.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 til-20240212_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 til-20240212_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 12, 2024
Cover [Abstract]  
Document Type 8-K
Entity Registrant Name Instil Bio, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40215
Entity Tax Identification Number 83-2072195
Entity Address, Address Line One 3963 Maple Avenue, Suite 350
Entity Address, City or Town Dallas
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75219
City Area Code 972
Local Phone Number 499-3350
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.000001 par value
Trading Symbol TIL
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Flag false
Entity Central Index Key 0001789769
Document Period End Date Feb. 12, 2024
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://instilbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports til-20240212.htm til-20240212.xsd til-20240212_lab.xml til-20240212_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "til-20240212.htm": { "nsprefix": "til", "nsuri": "http://instilbio.com/20240212", "dts": { "inline": { "local": [ "til-20240212.htm" ] }, "schema": { "local": [ "til-20240212.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "labelLink": { "local": [ "til-20240212_lab.xml" ] }, "presentationLink": { "local": [ "til-20240212_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "report": { "R1": { "role": "http://instilbio.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "til-20240212.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "til-20240212.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://instilbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001789769-24-000027-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001789769-24-000027-xbrl.zip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til-20240212_htm.xml IDEA: XBRL DOCUMENT 0001789769 2024-02-12 2024-02-12 false 0001789769 8-K 2024-02-12 Instil Bio, Inc. DE 001-40215 83-2072195 3963 Maple Avenue, Suite 350 Dallas TX 75219 972 499-3350 false false false false Common Stock, $0.000001 par value TIL NASDAQ true false